MILPITAS, Calif. – Digital diabetes solution provider Bigfoot Biomedical has raised $55 million in Series B funding to support ongoing product development, clinical trials and commercialization for its Class III investigational systems. Those systsms include Bigfoot Loop, an infusion pump-based closed loop automated insulin delivery system; and Bigfoot Inject, a connected insulin pen-based decision support system for people on injection therapy. The round included funding from Abbott, which partnered with Bigfoot last summer to develop and commercialize diabetes management systems. The two companies integrated the Abbott FreeStyle Libre glucose-sensing technology as the centerpiece for glucose monitoring capabilities within Bigfoot’s ecosystem of insulin delivery solutions. “Abbott’s inclusion in our financing speaks to our two companies’ alignment of vision for changing the paradigm of care for people with insulin-requiring diabetes,” said Jeffrey Brewer, president and CEO of Bigfoot Biomedical, in a statement.
You are here: / / Bigfoot Biomedical to advance digital diabetes solution with $55M